- Generic name
- Tofacitinib
- Strength
- 10 mg
- Dosage form
- Tablet
- Manufactured by
- Opsonin Pharma Limited
Xelnib XR 11 Tablet
About Xelnib XR 11 10 mg Tablet
Xelnib XR 11 10 mg is a tablet product of Opsonin Pharma Limited that contains Tofacitinib. It is an immunosuppressant medicine, so it is meant for people whose condition has been assessed by a doctor.
There are 13 brands of Tofacitinib listed in Bangladesh. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.
What is Xelnib XR 11 10 mg Tablet?
Xelnib XR 11 is a tablet from Opsonin Pharma Limited, with the generic name Tofacitinib. It may be prescribed alone or together with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. Xelnib XR 11 tablet is a medicine that contains Tofacitinib in a strength of 10 mg. Ask your doctor or pharmacist about anything you are unsure of.
Uses of Xelnib XR 11
It is an immunosuppressant medicine, so it is meant for people whose condition has been assessed by a doctor. The same medicine is also used for psoriatic arthritis together with nonbiologic DMARDs, and for ulcerative colitis. Ask the doctor whether it suits your condition.
How to use Xelnib XR 11
Take Xelnib XR 11 tablet exactly as your doctor prescribes. Xelnib XR 11 is taken by mouth. Swallow the tablet with water. The dose and course are decided by your doctor based on your condition and other medicines you take. Do not change the dose or stop treatment on your own.
Side effects of Xelnib XR 11
The most common side effects reported in the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis (inflammation of the nose and throat). Some people may have other effects. Because Tofacitinib affects the immune system, serious infections can occur. Contact your doctor if you notice anything unusual after taking it. Tell your doctor promptly if you notice signs of infection, such as fever, or any unusual symptom.
Safety and precautions
Xelnib XR 11 is not to be started during an active serious infection, including a localised one, and it should be used with caution in people at higher risk of gastrointestinal perforation. Your doctor may arrange laboratory monitoring because of possible changes in blood cells, liver enzymes and lipids. It is pregnancy category C; there are no adequate studies in pregnant women, and it should be used only if the potential benefit justifies the potential risk to the fetus. Tell your doctor about all the other medicines you take.
Frequently asked questions
What does Xelnib XR 11 treat?
It is an immunosuppressant medicine, so it is meant for people whose condition has been assessed by a doctor. The same medicine is also used for psoriatic arthritis together with nonbiologic DMARDs, and for ulcerative colitis.
How is Xelnib XR 11 used?
Take Xelnib XR 11 tablet exactly as your doctor prescribes. Xelnib XR 11 is taken by mouth.
What are the side effects of Xelnib XR 11?
The most common side effects reported in the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis (inflammation of the nose and throat). Some people may have other effects.
Who should be careful with Xelnib XR 11?
Xelnib XR 11 is not to be started during an active serious infection, including a localised one, and it should be used with caution in people at higher risk of gastrointestinal perforation. Your doctor may arrange laboratory monitoring because of possible changes in blood cells, liver enzymes and lipids.
Indications
Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Pharmacology
Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
Dosage & Administration
Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
Interaction
- Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
- Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
- Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
Side Effects
Pregnancy & Lactation
It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
Precautions & Warnings
- Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections.
- Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
- Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
- Immunizations: Live vaccines: Avoid use with Tofacitinib.
- Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
Storage Conditions
Alternative brands of Tofacitinib
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.